A new study suggests that risk factors and biomarkers related to Alzheimer’s disease are associated with cognition much earlier in life than previously recognized. The study highlights significant associations between cognition and Alzheimer’s disease risk factors as young as ages 24 to 44 and underscores the importance of early prevention. This is the first study to systematically examine Alzheimer’s disease risk factors, including biomarkers related to cognitive impairment in a large group of generally healthy middle-aged individuals in the U.S.

Research shows that instead of special protection against long COVID, vaccines kept children and adolescents from developing the condition by blocking COVID-19 infections in the first place 

A new study published in JAMA Internal Medicine found that hospitalized patients with alcohol use disorder who began taking the AUD medication naltrexone before they were discharged were able to reduce heavy drinking in the three-month period following their hospital stay. The findings specifically showed that both forms of naltrexone, which is offered as a pill or as an extended-release injectable, were similarly effective at reducing patients’ alcohol consumption. After three months of treatment, heavy drinking within the last 30 days decreased by approximately 38 percentage points among patients who took the oral version of naltrexone, compared to about a 46 percentage-point decrease among patients who received the injectable version of the medication.

A new study offers insight into what is happening in our brains when our working memory must use its limited resources to remember multiple things. Researchers found that two parts of the brain work together to ensure that more brain resources are given to remember a priority item when a person is juggling more than one item in memory.